Abstract：
Small biopsies of lung are routinely obtained by many methods, including several that result in cytologic specimens. Because lung cancer is often diagnosed at a stage for which primary resection is not an option, it is critical that all diagnostic, predictive, and prognostic information be derived from such small biopsy specimens. As the number of available diagnostic and predictive markers expands, cytopathologists must familiarize themselves with current requirements for specimen acquisition, handling, results reporting, and molecular and other ancillary testing, all of which are reviewed here.
摘要：
肺的小活检通常通过许多方法获得，包括几个导致细胞学标本。因为肺癌通常被诊断为无法进行原发性切除术的阶段，至关重要的是，所有的诊断，预测性，和预后信息来自这样的小活检标本。随着可用诊断和预测标志物数量的增加，细胞病理学家必须熟悉标本采集的当前要求，处理,结果报告，以及分子和其他辅助测试，所有这些都在这里回顾。
